Zhejiang Orient Gene Biotech Co., Ltd. / Fundamentals
Income statement
- Net revenue
€97.89M - Cost of goods sold
€65.92M - Gross profit
€31.98M - SG&A expenses
€25.18M - R&D expenses
€21.35M - EBITDA
-€68.31M - D&A
€0.00 - EBIT
-€70.46M - Interest expenses
€1.15M - EBT
-€72.39M - Tax expenses
-€2.28M - Net income
-€65.10M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€3.48M - Changes in working capital
€0.00 - Operating cash flow
-€9.83M - Capex
€90.08M - Other investing cash flow
€89.97M - Net investing cash flow
€44.77M - Total cash dividends paid
-€1.54M - Issuance of common stock
€0.00 - Debt repayment
-€30.55M - Other financing cash flow
-€3.04M - Net financing cash flow
-€35.13M - Foreign exchange effects
€2.40M - Net change in cash
-€2.07M - Cash at end of period
€173.89M - Free cash flow
€80.25M
Balance sheet
- Cash and cash equivalents
€301.20M - Cash and short-term investments
€339.35M - Total receivables
€24.60M - Inventory
€37.71M - Other current assets
€18.38M - Total current assets
€420.04M - Property, plant & equipment
€336.64M - Goodwill
€0.00 - Intangible assets
€78.50M - Long-term investments
€0.00 - Other non-current assets
€49.15M - Total non-current assets
€496.64M - Total assets
€916.68M - Accounts payable
€54.56M - Short-term debt
€20.23M - Other current liabilities
€24.17M - Total current liabilities
€99.68M - Long-term debt
€17.38M - Deferred tax liabilities
€13.19K - Other non-current liabilities
€1.71M - Total non-current liabilities
€22.30M - Total liabilities
€121.98M - Common stock
€24.28M - Retained earnings
€725.16M - Other equity
€0.00 - Total equity
€794.70M - Total liabilities and shareholders' equity
€916.68M
Company information
- Market capitalization
€628.69M - Employees
2.2K - Enterprise Value
€2.81B
Company ratios
- Gross margin
-
32.7% Worse than peer group: 51.9% - EBITDA margin
-
-69.8% Much worse than peer group: 25.8% - EBIT margin
-
-72.0% Much worse than peer group: 17.7% - EBT margin
-
-73.9% Much worse than peer group: 19.5% - Net margin
-
-66.5% Much worse than peer group: 16.6% - ROE
-
-8.2% Much worse than peer group: 17.8% - ROA
-
-7.1% Much worse than peer group: 13.4% - Asset turnover
-
10.7% Much worse than peer group: 54.8% - FCF margin
-
-102.1% Much worse than peer group: 3.1% - FCF yield
-15.9% - Efficiency ratio
169.8% - Net sales per employee
-
€43.88K - Net income per employee
-
-€29.18K